Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide

Key Terms

biomarker medical

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

mild cognitive impairment (mci) medical

Mild cognitive impairment (MCI) is a condition where a person experiences noticeable but not severe problems with memory, thinking, or decision-making. It can be seen as a warning sign that cognitive health is changing, but it does not yet interfere significantly with daily life. For investors, understanding MCI is important because it may indicate increased risk of developing more serious conditions like dementia, which can impact financial planning and long-term decision-making.

alzheimer’s disease medical

A progressive brain disorder that gradually erodes memory, thinking and the ability to perform everyday tasks, similar to a computer slowly losing files and processing speed. It matters to investors because its large and growing patient population drives demand for treatments, long-term care, diagnostics and related services, making clinical trial results, regulatory decisions and patent exclusivity major value drivers for healthcare and biotech companies.

Collaboration Aims to Expand Access to Early Detection of Potential Disease Marker

BILLERICA, Mass.--(BUSINESS WIRE)-- Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on identifying asymptomatic risks for chronic conditions in community health settings. Through the partnership, Life Line Screening will offer Lucent’s non-invasive blood based biomarker test nationally, with programs in Florida, California, and Texas already underway. This partnership supports the goals of both organizations to provide non-invasive, easily accessible testing in the general public.

According to the Alzheimer's Association, an estimated 7 million Americans are living with Alzheimer's disease today, with another 6-7 million experiencing symptoms of Mild Cognitive Impairment (MCI). These figures underscore the urgent public health need for scalable testing options that can facilitate earlier identification of the disease in its most treatable phase.

“Too many chronic conditions go undetected until they become life-altering events,” said Jim Waters, Chief Operating Officer at LLS. “By partnering with Lucent Diagnostics, we're able to continue to expand our mission of uncovering asymptomatic risks earlier and more equitably. This partnership has the potential to impact numerous lives by supporting more informed treatment pathways, and it’s something we’re excited to bring to communities across the country.”

Now available to their network, LLS can continue its mission by bringing cutting edge blood tests in an accessible and convenient way. Through their mobile delivery model, LLS will provide testing opportunities in local venues such as community centers, churches, and senior centers. The results of these tests can then be shared to help primary care physicians facilitate early intervention and proactive lifestyle management for adults.

“Scientific rigor shouldn’t stop at the laboratory door. Through LLS, Lucent Diagnostics is bringing validated, high-quality science into community testing networks, helping ensure that everyone has access to information for use by their physician and not only in a research setting. This is a critical step toward earlier, more reliable detection of Alzheimer’s Disease,” says Zachary Fernandes, Quanterix General Manager for Lucent Diagnostics.

Life Line Screening is a national provider operating in the 48 contiguous states. By hosting over 15,000 community events annually, they provide a scalable infrastructure that reaches individuals in both major metropolitan areas and underserved rural regions. To learn more about LLS, visit www.lifelinescreening.com. To learn more about Lucent Diagnostics and Quanterix, visit www.lucentdiagnostics.com.

About Lucent Diagnostics
Lucent Diagnostics, a commercial brand of Quanterix, was created in 2023 to deliver revolutionary tools that aid in the earlier detection of cognitive disease. Powered by the ultra-sensitive Simoa^® technology, Lucent Diagnostics bridges the gap between research and clinical use by offering products and services designed specifically to meet the separate needs of institutions and healthcare providers. With more than a decade of proven success within the neurology research space, supported by thousands of publications and partnerships, Quanterix aims to directly impact the landscape of cognitive disease through its commercial brand, Lucent Diagnostics. For more information, please visit www.LucentDiagnostics.com

About Life Line Screening Partners
Established in 1993, Life Line Screening is the nation’s leading provider of community-based preventive health screenings. The Company has empowered more than 11 million people to understand their health risks and take proactive steps toward maintaining their well-being. Life Line Screening serves over 15,000 locations across the US annually.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260302958140/en/

Quanterix Media Contact:

media@quanterix.com

Investor Relations Contact:

Joshua Young

(508) 846-3327 - mobile

jyoung@quanterix.com    

Source: Quanterix